Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high expectations from early-phase studies, the drug initially did not meet the ...

At HUAWEI CONNECT 2024, Executive Director of the Board of Huawei and CEO of Huawei Cloud Zhang Ping'an delivered a keynote ...

The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to ...

Oncologists are perturbed by the increase in early-onset tumors and the potential role of lifestyle, though this may not ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

NEW YORK, Sept. 20, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...

J&J's high expectations for Rybrevant are driven mainly by its August approval with Lazcluze, which outperformed Tagrisso in ...

The challenge persists, but, with a renewed focus from regulatory bodies and trial sponsors alike on improving enrolment ...

In a medical breakthrough, scientists were able to kill 99 per cent of bone cancer cells without causing any harm to the ...

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act ...

039). At the 2024 ESMO Congress, longer term follow-up results from MARIPOSA-2 were presented. Patients assigned amivantamab plus chemotherapy had a median OS of 17.7 months (95% CI, 16.0-22.4) ...

Investorideas ( ), a go-to investing platform, releases the second of a two-part series looking at news and developments for the <a target=_blank ...